In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 206 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI continuam a encontrá-las. Abra sempre a notícia original e fale com o seu médico antes de tirar conclusões sobre o seu caso. Última recolha: 17 nov 2026, 21:48.
Tuesday, November 17
Imunoterapia amplia a sobrevida de pacientes com mieloma múltiploPortal Drauzio Varella (Brasil) · 18:03 Patients and associationsBrazilPTDo transplante à imunoterapia, novos tratamentos estão mudando as perspectivas dos pacientes com mieloma múltiplo. Saiba mais.
Monday, 16/11
Sanofi and the Alliance Pharmaceutical PanCanadian sign a letter of intent for Sarclisa® (isatuximab), a further step towards public access for newly diagnosed patients with multiple myeloma who are not eligible for a transplant.PR Newswire Canada (Canada) · 14:15 TreatmentsCan you provide the French text you want me to translate?FR/CNW/ -- Sanofi announced today the happy conclusion of negotiations with the Canadian Alliance Pharmaceutical (CPP), marked by the signing of a...
Sanofi and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Sarclisa®(isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patientsPR Newswire Canada (Canadá) · 14:15 Doentes e associaçõesCanadá
Quarta, 21/10
Allogeneic transplantation for plasma cell myeloma clears pre-transplant clonal haematopoiesis and is associated with a low rate of myeloid neoplasm post-cytotoxic-therapyNature (Reino Unido) · 07:00 TratamentosReino Unido
Quarta, 30/09
Overview | Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable | GuidanceNICE website (Reino Unido) · 07:00 TratamentosReino Unido
Sexta, 11/09
New score improves survival prediction in elderly patients with multiple myeloma.My Hematologia — pesquisa "mieloma" (página 2) (Portugal) · 14:31 Patients and associationsPortugalPTAn international study has developed a new prognostic model for elderly patients with multiple myeloma who are not eligible for transplant, offering a more accurate alternative to traditional systems focused solely on the disease. Researchers created the Myeloma Elderly Prognostic Score (MEPS), a tool…
Sábado, 05/09
Multiple Myeloma: At the IMSS with targeted therapies and autologous transplant, treatment options are expanded.IMSS (Mexico) · 07:00 TreatmentsMéxicoES
Notícias com mais de 90 dias: só o título e o link para a fonte.
Pay attention to old news. Marked as. about 1 year 2 years 5 years 10 years You may also want to check that the information is still up to date: treatments, approvals and prices change quickly. Always confirm with your hematology team.
Access and public health
- FDA approves quadruplet with daratumumab in multiple myeloma without indication for transplant ↗ · Oncology News Central · 28/01/2026
- Four-drug regimen based on DARZALEX and FASPRO® approved in the US for newly diagnosed patients with multiple myeloma who are not eligible for transplant. ↗ · PR Newswire · 27/01/2026
Patients and associations
- Why should transplantation be considered earlier in patients with multiple myeloma? about 1 year · Roswell Park Comprehensive Cancer Center · June 24, 2025
- Isatuximab, lenalidomide, bortezomib and dexamethasone in the induction of newly diagnosed patients with eligibility for transplant: final analysis of progression-free survival part 1 of the GMMG-HD7 phase 3 trial. about 1 year · International Myeloma Society · January 30, 2025
- Stem cell transplant in multiple myeloma: Paul’s story ↗ 2 years · Roswell Park Comprehensive Cancer Center · 05/08/2024
Research
- Phase 3 study of teclistamab with lenalidomide, and teclistamab alone, versus lenalidomide in maintenance after autotransplant in newly diagnosed multiple myeloma: preliminary safety results from the MajesTEC-4/EMN30 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Phase 2 study of inductions with teclistamab in patients newly diagnosed with transplant eligibility: results of the GMMG-HD10/DSMM-XX (MajesTEC-5) trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Efficacy and safety of Isa-KRd induction prior to adapted consolidation based on response in newly diagnosed multiple myeloma with indication for transplant: interim analysis of the IFM2020-02 MIDAS study ↗ 2 years · International Myeloma Society · 27/09/2024
Treatments
- Treatment induction based on teclistamab in patients with multiple myeloma who are eligible for transplant and with recent diagnosis: a phase 2 trial. ↗ · Nature · 25/06/2026
- Isatuximab in combination for multiple myeloma who are not yet treated when a transplant is not possible ↗ about 1 year · NICE website · 24/09/2025
- Summary | Daratumumab with lenalidomide and dexamethasone in the treatment of multiple myeloma who are not treated when transplantation is not possible | Recommendation ↗ 3 years · NICE website · 25/10/2023
- Motexafortide and stem cell transplants in the treatment of multiple myeloma ↗ 3 years · National Cancer Institute (.gov) · 07/07/2023
- Daratumumab in combination for multiple myeloma who is not treated when transplant is feasible ↗ 4 years ago · NICE website · 02/02/2022
- Few relapses 7 years after transplant in multiple myeloma ↗ 6 years · CancerNetwork · 17/06/2020
- Treatment of Acute Kidney Injury Caused by Multiple Myeloma with High-Flow Polisher Filter | Dialysis and Transplant ↗ 7 years · www.elsevier.com · 08/04/2019
- Recovery after a stem cell transplant in myeloma ↗ 8 years · Cancer Research UK · 30/06/2018
- Stem cell transplant in myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
